1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 1998;83:2638-48.
[CROSSREF] [PUBMED]
2. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-42.
[CROSSREF] [PUBMED]
3. Nikiforov YE, Biddinger PW, Thompson LDR. Diagnostic pathology and molecular genetics of the thyroid. 2nd ed. Philadelphia: Wolters Kluwer; 2013.
4. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016;2:1023-9.
[CROSSREF] [PUBMED] [PMC]
5. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 2016;101:264-74.
[CROSSREF] [PUBMED]
6. Bychkov A, Hirokawa M, Jung CK, Liu Z, Zhu Y, Hong SW, et al. Low rate of noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice. Thyroid 2017;27:983-4.
[CROSSREF] [PUBMED]
7. Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016;375:1054-67.
[CROSSREF] [PUBMED] [PMC]
8. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
9. Kakudo K, Bychkov A, Bai Y, Li Y, Liu Z, Jung CK. The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives. Pathol Int 2018;68:641-64.
[CROSSREF] [PUBMED]
10. Song E, Jeon MJ, Oh HS, Han M, Lee YM, Kim TY, et al. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma? Eur J Endocrinol 2018;179:135-42.
[CROSSREF] [PUBMED]
11. Ito Y, Hirokawa M, Uruno T, Kihara M, Higashiyama T, Takamura Y, et al. Prevalence and biological behaviour of variants of papillary thyroid carcinoma: experience at a single institute. Pathology 2008;40:617-22.
[CROSSREF] [PUBMED]
12. Jiang C, Cheng T, Zheng X, Hong S, Liu S, Liu J, et al. Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. Cancer Manag Res 2018;10:465-72.
[CROSSREF] [PUBMED] [PMC]
13. Chow SM, Chan JK, Law SC, Tang DL, Ho CM, Cheung WY, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: clinical features and outcome. Eur J Surg Oncol 2003;29:446-9.
14. Akaishi J, Sugino K, Kameyama K, Masaki C, Matsuzu K, Suzuki A, et al. Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma. World J Surg 2015;39:1728-35.
[CROSSREF] [PUBMED]
15. Chereau N, Giudicelli X, Pattou F, Lifante JC, Triponez F, Mirallie E, et al. Diffuse sclerosing variant of papillary thyroid carcinoma is associated with aggressive histopathological features and a poor outcome: results of a large multicentric study. J Clin Endocrinol Metab 2016;101:4603-10.
[CROSSREF] [PUBMED]
16. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol 2004;86:44-54.
[CROSSREF] [PUBMED]
17. Lee YS, Kim Y, Jeon S, Bae JS, Jung SL, Jung CK. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review. Int J Clin Exp Pathol 2015;8:7988-97.
[PUBMED] [PMC]
18. Ieni A, Barresi V, Cardia R, Licata L, Di Bari F, Benvenga S, et al. The micropapillary/hobnail variant of papillary thyroid carcinoma: a review of series described in the literature compared to a series from one southern Italy pathology institution. Rev Endocr Metab Disord 2016;17:521-7.
[CROSSREF] [PUBMED]
19. Teng L, Deng W, Lu J, Zhang J, Ren X, Duan H, et al. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Oncotarget 2017;8:22023-33.
[CROSSREF] [PUBMED] [PMC]
20. Ito M, Bogdanova T, Zurnadzhy L, Saenko V, Rogounovitch T, Mitsutake N, et al. Morphological difference in adult thyroid papillary carcinoma between Japan and Ukraine. Endocr J 2014;61:1221-8.
[CROSSREF] [PUBMED]
21. Sugitani I, Toda K, Yamamoto N, Sakamoto A, Fujimoto Y. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. World J Surg 2010;34:1265-73.
[CROSSREF] [PUBMED]
22. Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, Miyauchi A. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 2009;33:958-62.
[CROSSREF] [PUBMED]
23. Falvo L, Giacomelli L, D’Andrea V, Marzullo A, Guerriero G, de Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 2006;72:438-44.
[CROSSREF] [PUBMED]
24. Lam AK, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 2006;13:176-81.
[CROSSREF] [PUBMED]
25. Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, et al. Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 2008;99:1908-15.
[CROSSREF]
26. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 2001;25:1478-84.
27. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics of Tumours of Endocrine Organs. 3rd ed. Lyon: IARC Press; 2004.
28. Ito Y, Hirokawa M, Miyauchi A, Higashiyama T, Kihara M, Miya A. Prognostic significance of the proportion of tall cell components in papillary thyroid carcinoma. World J Surg 2017;41:742-7.
[CROSSREF] [PUBMED]
29. Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget 2016;7:40792-9.
[CROSSREF] [PUBMED] [PMC]
30. Lee SH, Jung CK, Bae JS, Jung SL, Choi YJ, Kang CS. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma. Diagn Cytopathol 2014;42:11-7.
[CROSSREF] [PUBMED]
31. Kim SY, Kim T, Kim K, Bae JS, Kim JS, Jung CK. Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans. J Pathol Transl Med 2020;54:310-7.
[CROSSREF] [PUBMED] [PMC]
32. Shin JH. Ultrasonographic imaging of papillary thyroid carcinoma variants. Ultrasonography 2017;36:103-10.
[CROSSREF] [PUBMED] [PMC]
33. Baek HJ, Kim DW, Shin GW, Heo YJ, Baek JW, Lee YJ, et al. Ultrasonographic features of papillary thyroid carcinomas according to their subtypes. Front Endocrinol (Lausanne) 2018;9:223.
[CROSSREF] [PUBMED] [PMC]
34. Choi YJ, Shin JH, Kim JH, Jung SL, Son EJ, Oh YL. Tall cell variant of papillary thyroid carcinoma: sonographic and clinical findings. J Ultrasound Med 2011;30:853-8.
[PUBMED]
35. Ha EJ, Moon WJ, Na DG, Lee YH, Choi N, Kim SJ, et al. A multicenter prospective validation study for the Korean Thyroid Imaging Reporting and Data System in patients with thyroid nodules. Korean J Radiol 2016;17:811-21.
[CROSSREF] [PUBMED] [PMC]
36. Yun MB, Sundar PS, Lan PY, Ying SX, Hua Z. Ultrasonographic features of diffuse sclerosing variant of papillary thyroid carcinoma. J Med Ultrasound 2011;19:41-6.
[CROSSREF]
37. Chong Y, Shin JH, Oh YL, Han BK, Ko EY. Cribriform-morular variant of papillary thyroid carcinoma: ultrasonographic and clinical characteristics. Thyroid 2013;23:45-9.
[CROSSREF] [PUBMED]
38. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010;34:44-52.
[CROSSREF] [PUBMED]
39. Vuong HG, Kondo T, Pham TQ, Oishi N, Mochizuki K, Nakazawa T, et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol 2017;176:433-41.
[CROSSREF] [PUBMED]
40. Chen CC, Chen WC, Peng SL, Huang SM. Diffuse sclerosing variant of thyroid papillary carcinoma: diagnostic challenges occur with Hashimoto’s thyroiditis. J Formos Med Assoc 2013;112:358-62.
[CROSSREF] [PUBMED]
41. Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 2007;20:779-87.
[CROSSREF] [PUBMED]
42. Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Histopathology 2016;69:45-53.
[CROSSREF] [PUBMED]